{"analyses":[{"ciLowerLimit":"0.487","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.722","estimateComment":"HR with 95% CI was estimated using a stratified Cox proportional hazards regression model using the IWRS stratification factors (geographical regions and etiology of liver disease).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.593","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.76","upperLimit":"4.47","value":"3.48"},{"groupId":"OG001","lowerLimit":"1.58","upperLimit":"2.76","value":"2.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"description":"TTP was defined as the time from randomization to the first radiographically documented PD. PD was defined, using RECIST v1.1 criteria, as ≥20% increase in SOD of target lesions, taking as reference smallest sum on study (including baseline sum if it was the smallest). Sum must show an absolute increase of ≥5 mm. Appearance of ≥1 new lesions and unequivocal progression of existing non-target lesions were considered progression. Participants without PD were censored at the day of the last adequate tumor assessment. Progression occurred immediately after ≥2 missed tumor assessments and were censored at the day of the last adequate tumor assessment prior to the missing assessments. Participants who began new anticancer therapy were censored at the day of their last adequate tumor assessment prior to start of new anticancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"ITT Population: All randomized participants. Participants censored: Ram=86, Pl=52.","reportingStatus":"POSTED","timeFrame":"Randomization to PD (up to 36 months)","title":"Time to Radiographic Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}